Skip to main content

Posts tagged with "Diabetes and Obesity"

  • Business and Markets

    Mannkind and Afrezza: Reality Intrudes. Or Should, Anyway.

    Inhaled insulin probably has no particular effects on the central nervous system. But there’s something about the idea of inhaled insulin that makes people lose their minds. That’s the only conclusion I can draw after years of watching this area. Pfizer led the way with a long, expensive collaboration that produced Exubera, the first in… Read More
  • Clinical Trials

    Fewer Die – But Why?

    Well, here’s an interesting situation: a drug that seems to have a definite benefit, but not for the reasons anyone expected, and not for reasons that anyone even understands. The drug is Jardiance (empagliflozin), for diabetes, and the benefit is a flat-out survival benefit, a significant effect on cardiovascular mortality. As Matthew Herper… Read More
  • Diabetes and Obesity

    Zebrafish, Finally Taking Over as Foretold

    The idea of phenotypic screening is not new, but once you bring up the topic, you find that different people have different ideas about what a phenotypic screen really is. As has been discussed around here before, not everyone buys into the concept of a cell-based screen as “phenotypic”, but I’m willing to believe in the… Read More
  • Animal Testing

    Is Everything Getting Fatter?

    Here’s a weird and interesting paper to think about. There’s an unfortunately clear trend in human populations towards obesity, which seems to have been especially noticeable over the last thirty years or so. (I believe that the average-thinnest US state today would have been the fattest state in 1980, just to give one vivid example).… Read More
  • Alzheimer's Disease

    On the FDA, Drug Approvals, and Not Knowing Enough

    It doesn’t seem to have generated many headlines, but the FDA recently released a report (PDF) on the pace of drug development. Titled “Targeted Drug Development: Why Are Many Diseases Lagging Behind”, it seems to be motivated, at least in part, by a desire to answer “Not Because of Us!” The agency goes into some deta… Read More
  • Diabetes and Obesity

    Unkind to Mannkind

    Last time I mentioned Mannkind and their inhaled-insulin product (Afrezza) around here was when Oliver Brandicourt was announced as taking over at Sanofi. But I’ve had unkind things to say about them over the years, and their retail-investor cult is one of the most bizarre I’ve ever seen. So now that Afrezza is launched, and… Read More
  • Cardiovascular Disease

    How Not to Handle Your Clinical Data

    We turn now to Orexigen, one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug (Contrave, a sustained release formulation combining the known drugs naltrexone and bupropion) had cardiovascular benefits above and beyond its weight-loss effects. P… Read More
  • Biological News

    Is Irisin Real?

    In 2012, the Spiegelman lab at Harvard reported a new peptide hormone, irisin (derived from a known precursor, FNDC5), that seemed to be involved in (among other things) brown-fat-like energy usage and the beneficial effects of exercise. There have been questions from other researchers about this work, but even this time last year work was… Read More
  • Diabetes and Obesity

    Dinitrophenol: A Possible Comeback

    I’ve mentioned metabolic uncoupling as a possible diabetes therapy. The idea is that your mitochondria will plow though large amounts of lipids under these conditions, and there’s plenty of evidence that knocking down free fatty acids and tissue lipid stores would be of great benefit for Type II patients. The problem is that this therap… Read More
  • Business and Markets

    Bonne Chance, Brandicourt

    Sanofi’s CEO hunt has ended, and the roue de la fortune has pointed to Bayer’s Olivier Brandicourt. (I’m tempted to keep dropping French phrases every couple of lines, but I figure that no one will stand for it, so you can work them in mentally as appropriate). But before his two years at Bayer, Brandicourt… Read More